HC Wainwright Reiterates Buy Rating on NVCR

On June 18, 2026, HC Wainwright reiterated its buy rating on NVCR, setting a price target of $46. This reflects continued confidence in the company's prospects despite its current trading price of approximately $14.71.

Other Institutional Activity in NVCR

Institutional investors have been actively adjusting their positions in NVCR. FMR LLC grew its holdings by 272,170 shares, ending with 17,069,149 shares valued at about $186.1 million. In contrast, BlackRock, Inc. reduced its stake by 347,683 shares, maintaining 13,193,765 shares worth approximately $143.8 million. Soleus Capital Management, L.P. significantly increased its holdings by 1,961,726 shares, bringing its total to 10,492,391 shares valued at $114.4 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both established new positions with 6,251,701 and 4,682,064 shares, respectively. Meanwhile, Morgan Stanley trimmed its holdings by 528,369 shares, retaining 4,541,526 shares worth about $49.5 million.

NVCR Stock Snapshot

NVCR shares are currently trading near $14.71. The stock has seen recent fluctuations, with institutional investors making notable adjustments to their holdings. These movements reflect varying strategies and confidence levels among major investors.

Insider Buying and Selling at NovoCure Limited

Recent insider activity at NVCR includes several transactions. On June 4, 2026, CEO Leonard Frank sold 34,273 shares at an average price of $17.93. Meanwhile, on June 3, 2026, Martin Madden, along with Anthony Vernon, Timothy Scannell, and David Hung, each acquired shares in the company. These purchases were made at a price of $0, indicating potential stock grants or awards.

Analysts Set New Price Targets

On June 18, 2026, HC Wainwright & Co. reiterated its buy rating on NVCR, setting a price target of $46. In May, Wells Fargo maintained a hold rating with a $17 target, while Evercore ISI Group kept its buy rating and a $20 target. The analyst consensus suggests a mixed outlook, with varying levels of optimism about NVCR's future performance.

About NVCR

NVCR is a healthcare company focused on the development and commercialization of treatments for solid tumor cancers. Based in the United States, the company is known for its innovative approaches to cancer therapy. NVCR's mission is to improve the lives of cancer patients through groundbreaking research and development.

Bottom Line

Analyst activity, insider transactions, and institutional movements provide a comprehensive view of NVCR's current market dynamics. HC Wainwright's reiterated buy rating and $46 price target underscore confidence in the company's long-term potential. Investors should consider these insights with the understanding that 13F filings and analyst ratings are backward-looking and may not reflect the most current positions or sentiments.